International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East by Amouzegar, A. et al.
www.kisupplements.org I SN pub l i c a f f a i r sInternational Society of Nephrology Global Kidney
Health Atlas: structures, organization, and services for
the management of kidney failure in the Middle East
Atefeh Amouzegar1, Ali K. Abu-Alfa2, Mona N. Alrukhaimi3, Aminu K. Bello4,23,
Mohammad A. Ghnaimat5, David W. Johnson6,7,8,23, Vivekanand Jha9,10,11, David C.H. Harris12,
Adeera Levin13, Marcello Tonelli14,15, Meaghan Lunney16, Syed Saad17, Maryam Khan18,
Deenaz Zaidi17, Mohamed A. Osman19, Feng Ye17, Ikechi G. Okpechi17,20,21 and Shahrzad Ossareh22;
on behalf of the ISN Middle East Regional Board
1Division of Nephrology, Department of Medicine, Firoozgar Clinical Research Development Center, Iran University of Medical Sciences,
Tehran, Iran; 2Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon;
3Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates; 4Division of Nephrology and Immunology, Department of
Medicine, University of Alberta, Edmonton, Alberta, Canada; 5Nephrology Division, Department of Internal Medicine, The Specialty Hospital,
Amman, Jordan; 6Department of Nephrology, Metro South and Ipswich Nephrology and Transplant Services, Princess Alexandra Hospital,
Brisbane, Queensland, Australia; 7Centre for Kidney Disease Research, University of Queensland at Princess Alexandra Hospital, Brisbane,
Queensland, Australia; 8Translation Research Institute, Brisbane, Queensland, Australia; 9George Institute for Global Health, University of
New South Wales, New Delhi, India; 10School of Public Health, Imperial College, London, UK; 11Manipal Academy of Higher Education,
Manipal, India; 12Centre for Transplantation and Renal Research, The Westmead Institute for Medical Research, University of Sydney,
Westmead, New South Wales, Australia; 13Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British
Columbia, Canada; 14Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 15Pan-American Health Organization/World
Health Organization’s Collaborating Centre in Prevention and Control of Chronic Kidney Disease, University of Calgary, Calgary, Alberta,
Canada; 16Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; 17Department of Medicine,
University of Alberta, Edmonton, Alberta, Canada; 18Faculty of Science, University of Alberta, Edmonton, Alberta, Canada; 19Department of
Family Medicine, University of Ottawa, Ottawa, Ontario, Canada; 20Division of Nephrology and Hypertension, University of Cape Town, Cape
Town, South Africa; 21Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa; and 22Division of
Nephrology, Department of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, IranKidney failure is the permanent impairment of kidney
function associated with increased morbidity,
hospitalization, and requirement for kidney replacement
therapy. A total of 11 countries in the Middle East region
(84.6%) responded to the survey. The prevalence of chronic
kidney disease in the region ranged from 5.2% to 10.6%,
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services were available in most countries of the region.
Public funding covered the costs of nondialysis chronic
kidney disease care in two-thirds of countries, and kidneyCorrespondence: Shahrzad Ossareh, Section of Nephrology and Hemodi-
alysis Ward, Hasheminejad Kidney Center, Iran University of Medical Sciences,
Vanak Square, Tehran, 1969714713 Iran. E-mail: ossareh_s@hotmail.com
23AKB and DWJ are co-chairs for International Society of Nephrology
Global Kidney Health Atlas Project.
Received 2 October 2020; revised 9 December 2020; accepted 6 January
2021
Kidney International Supplements (2021) 11, e47–e56replacement therapy in nearly all countries. More than half
of the countries had dialysis registries; however, national
noncommunicable disease strategies were lacking in most
countries. The Middle East is a region with high burden of
kidney disease and needs cost-effective measures through
effective health care funding to be available to improve
kidney care in the region. Furthermore, well-designed and
sustainable health information systems are needed in the
region to address current gaps in kidney care in the region.
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Elsevier Inc. All rights reserved.K idney failure (KF) has become a major public healthissue around the world and is associated with excesscosts from kidney replacement therapy (KRT; dialysis
and kidney transplantation), hospitalization, morbidity, and
mortality.1 Although several countries in the Middle East have
an abundance of mineral resources, there are still several
challenges in the region in the capacity to provide adequate
kidney care for its people. Some of the challenges includee47
I SN pub l i c a f f a i r s A Amouzegar et al.: ISN-GKHA: Middle Eastongoing conflicts and wars,2 refugee crises and differences in
language,3 religious practices/beliefs,4 and culture.5 One study
suggested the presence of additional, less obvious challenges,
including variable availability of infrastructure, constraints on
health expenditure related to gross national income, lack of
data on kidney disease, and low-level awareness within the
medical community and the public about the advances of
therapeutic and preventive measures to reduce KF.6 Regional
bodies, such as the Middle East Society for Organ Trans-
plantation, have been formed as a platform for filling the gaps
and improving education, training, research, and collabora-
tion within the region.7 Despite these, there still remains a
significant gap of information on funding, availability,
accessibility, health information systems, and national stra-
tegies for kidney care in the region. We leveraged on available
data from the second iteration of the International Society of
Nephrology (ISN) Global Kidney Health Atlas to report on
various states of KF care in the Middle East region. The
methods for this research are described in detail elsewhere.8Results
Results of this study are presented in tables and figures and
broadly summarized into 2 categories: desk research (Tables 19–17
and 210,18–21, Figure 1, and Supplementary Table S1) and survey
administration (Figures 2–5 and Supplementary Figures S1–S5).
Setting. The Middle East is a geographic region covering
almost 7.208 million km2 that extends from the eastern shores
of the Mediterranean Sea to the Indian Ocean (Figure 1). The
region comprises 18 countries with a total population of >410
million people, with the most populous countries being Egypt,
Iran, Turkey, Iraq, and Saudi Arabia. Of the 18 countries in the
Middle East, 13 belong to the Arab community.22
However, the ISN Middle East region23 is a subset of these
countries, comprising Bahrain, Iran, Iraq, Jordan, Kuwait,
Lebanon, Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates,
West Bank and Gaza, and Yemen, with a total population of 243.7
million. Among these, Saudi Arabia has the largest land mass,
whereas the Islamic Republic of Iran (the only Persian-speaking
country in the region) has the largest population (Table 1).9
In 2017, gross national income per capita in the Middle
East and North Africa was US$13,763, ranging from
US$61,150 in Qatar to <US$2000 in Yemen (US$1460) and
Syria (US$1820).24 The outlook for economic growth in the
Middle East and North Africa dropped to 0.6% in 2019.25
Voluntary cuts to oil production, growing global economic
headwinds, and the marked contraction of Iran’s economy
due to rising geopolitical tensions are collectively responsible
for this downward revision from the 1.5% growth rate pro-
jected in April 2019. Despite the downward trend of the past
year, economic growth in the region is projected to rise to
2.6% in 2020 and to 2.9% in 2021.25 However, given the
recent crisis in the world economy due to the coronavirus
disease 2019 pandemic, these expectations are likely to
change. One of the important limiting factors to chronic
kidney disease (CKD) care delivery and research projects ine48the Middle East is the low gross national income in many
countries in the region.10
Current state of kidney care in the Middle East. The burden
of CKD and KF remains high in the Middle East and may be
growing faster than other world regions.26 The overall prev-
alence of KF reported in the Middle East in 2008 was 430 per
million population (pmp), and the pooled prevalence calcu-
lated in a recent study in the Middle East region was 360
pmp.26,27 Diabetes, glomerulonephritis, and hypertensive
nephrosclerosis were leading causes of CKD in the region;
however, many cases were frequently labeled as “unknown
causes” because of late referral and late patient presentation.10
Data from the region show that hemodialysis (HD) was the
most frequently used KRT modality, whereas peritoneal
dialysis (PD) was the least frequently used.10,28
Characteristics of contributing countries. Responses were
received from 11 (84.6%) countries in the ISN region (of 13
countries in the region), representing 243.7 million people
(87% of the regional population). The response rate for the
region was 80.6%, with most responses from nephrologists
(n ¼ 26 [90%]) and one response (3%) each for a non-
nephrologist physician, a nonphysician health professional,
and a policy maker. The World Bank classified approximately
half of the participating countries as high income (n ¼ 6
[54.5%]) and one-third as upper-middle income (n ¼ 4
[36.4%]). The total health expenditure, as a percentage of
gross domestic product in the region, ranged from 3.1% in
Qatar to 7.6% in Iran (Table 1).11,12
Burden of CKD and KF in the Middle East. The prevalence
of CKD in the Middle East ranged from 5.24% in Yemen
(low income) to 10.57% in Iran (upper-middle income).
The proportion of deaths and disability-adjusted life-years
attributed to CKD were highest in Saudi Arabia (high
income) and Jordan (upper-middle income)
(Supplementary Table S1).
Data on the prevalence of treated KF were available for
only 8 of the 13 countries in the region (Table 2).18–20 All 3
modes of KRT (long-term HD, PD, and kidney trans-
plantation) were available from most countries; Saudi Arabia
(826 pmp) and the United Arab Emirates (152 pmp) reported
the highest and lowest prevalence of treated KF in the region,
respectively. Lebanon reported the highest prevalence of HD
(668.5 pmp), whereas Qatar reported the highest prevalence
of long-term PD (104.5 pmp), although the prevalence of
long-term HD was still more than twice as high in Qatar
(296.4 pmp), indicating a preference of HD over PD.
The incidence of kidney transplantation was highest in
Iran (30.96 pmp) and lowest in Oman and the United Arab
Emirates (2.22 and 3.04 pmp, repectively) (Table 2).18–20 Iran
reported the highest incidence of deceased donor trans-
plantation (17.49 pmp), comprising 56.5% of transplants,
whereas Jordan had the highest incidence of living donor
transplantation (25.19 pmp), comprising 100% of trans-
plants. Of the 11 countries that provided transplant data, in 4
countries, kidneys from deceased donors were not used
(Jordan, Oman, Syria, and the United Arab Emirates).Kidney International Supplements (2021) 11, e47–e56
Table 1 | Health finance, service delivery, and workforce prevalence in ISN Middle East countries9–17
Country
World Bank








Annual cost KRTb (US$) and out-of-pocket
cost/% paid by patient from total costc
HD PD KT (first year)












Bahrain High 760 1,442,659 71.2 4.9 41,535 — 18,361
Iran, Islamic Rep. Upper-middle 1,648,195 83,024,745 1640.0 7.6 13,619/1–25 13,026/1–25 11,129/1–25
Iraq Upper-middle 438,317 40,194,216 649.3 5.5 —/51–75 —/26–50 —/51–75
Jordan Upper-middle 89,342 10,458,413 89.0 6.9 15,860/1–25 9855/0 26,839/100
Kuwait High 17,818 2,916,467 289.7 4.0 —/0 —/0 —/0
Lebanon Upper-middle 10,400 6,100,075 88.3 7.4 19,489/1–25 20,075/1–25 —/1–25
Oman High 309,500 3,494,116 190.1 3.8 —/1–25 —/0 —/0
Qatar High 11,586 2,363,569 339.5 3.1 —/1–25 —/1–25 —/1–25
Saudi Arabia High 2,149,690 33,091,113 1775.0 5.8 50,739/— 42,444/— 113,935/100
Syrian Arab Rep. Low 185,180 19,454,263 50.3 3.3 —/1–25 —/26–50 —/100
United Arab Emirates High 83,600 9,701,315 696.0 3.5 41,535/1–25 —/0 18,361/100
West Bank and Gaza Lower-middle 6220 4,635,207 21.2 — 17,259/0 —/— 17,465/0
Yemen Low 527,968 28,667,230 73.6 6.0 — — —
—, Data not reported/unavailable; GDP, gross domestic product; HD, hemodialysis; IQR, interquartile range; ISN, International Society of Nephrology; KRT, kidney replacement therapy; KT, kidney transplantation; PD, peritoneal
dialysis; PPP, purchasing power parity; Rep., Republic.
aEstimates are in US$ 2017.
bDetailed reference list on annual cost of KRT is available in the Supplementary Appendix.
cCost is in US$ 2016.
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e50Dialysis and transplantation services were funded by public
and private insurance systems in most countries in the Middle
East. Data registries for CKD and acute kidney injury were
scarce in most countries.
Health finance and service delivery for kidney care in the
Middle East. Funding for KRT was “publicly funded by
government” in 91% (n ¼ 10) of countries (vs. 43% [n ¼ 69]
globally), with the remaining 9% (n ¼ 1) funded “publicly by
government with some fees at the point of delivery”
(Figure 2). However, nondialysis CKD was “publicly funded
by government” in 64%, whereas “a mixture of public and
private funding” covered 27% of nondialysis CKD care in the
region. Surgical services, such as central venous catheter
insertion, HD fistula and graft creation, and insertion of PD
catheters, were also largely covered by public funds by gov-
ernment in 82% of countries for all services. The annual cost
of HD was lowest in Iran (US$13,619), with 1% to 25% out-
of-pocket (OOP) payment, and was highest in Saudi Arabia
(US$50,739), with data on OOP not available. Iran also had
the lowest cost of first year treatment for transplant patients
(US$11,361; OOP, 1%–25%), whereas Saudi Arabia had the
highest (US$113,935; OOP, 100%) (Table 1).11–17
Health workforce for kidney care in the Middle East. Data on
workforce showed similarities in number of nephrologists and
nephrology trainees in the Middle East region and globally
(Table 2).21 The median number of nephrologists in the region
was 8.08 pmp (vs. 9.95 pmp globally). The median number of
nephrologists was lowest in Iraq (2.49 pmp) and highest in
Lebanon (28.28 pmp), and 4 countries in the region (Kuwait,
Lebanon, Oman, and Qatar) had more nephrologists than the
global median. The median number of nephrology trainees was
also similar to the global median (1.82 versus 1.42 pmp,
respectively), and there were no nephrology trainees in West
Bank and Gaza (Table 2).18–20 There were shortages reported in
other categories of KF care providers in most countries, with
the shortages more severe for interventional radiologists for HD
and PD access; there were no shortages reported in Lebanon
(Supplementary Figure S1).
Capacity for KRT service provision in the Middle East. Although
all countries in the region had capacity for long-term HD
provision, there was more capacity for HD care than for PD in
the region (Figure 3 and Table 2).18–20 Lebanon had the highest
number of HD centers (11.9 pmp); the lowest was in Iraq (1.24
pmp), which also had the lowest number of PD centers (0.20
pmp) (Table 2).18–20 Home HD was reported to be “generally
available” in 9% of countries. All countries (100%) had capacity
to provide adequate HD (i.e., 3 times/week for 3-4 hours per
session). Capacity to provide adequate PD (i.e., 3–4 exchanges
per day) was reported to be “generally available” in 64% of
countries (Figure 3). The capacity to treat complications of KF
was readily available for most factors assessed in nearly all
countries (Supplementary Figure S2). When factors influencing
access to KRT were considered, neither geography nor patient
characteristics played significant roles in determining access
(Figure 4). Although the incidence and prevalence of kidney














Figure 1 | Map of Middle East countries participating in the International Society of Nephrology Global Kidney Health Atlas survey.
NIS, Newly Independent States.
A Amouzegar et al.: ISN-GKHA: Middle East I SN pub l i c a f f a i r sprevalence, 311 pmp), data on the number of kidney transplant
centers showed that Jordan had the highest (1.00 pmp).10 There
were no data on kidney transplant prevalence from Jordan,
Lebanon, Syria, United Arab Emirates, West Bank and Gaza,
and Yemen (Table 2).18–20 Standard organ procurement
frameworks were reported as “generally available” in 64% of
countries, whereas effective preventive therapies to control in-
fections in transplant patients, immunosuppression, and facil-
ities for monitoring immunosuppression drugs were available
in 100% (Figure 3).
Conservative kidney management was reported to be available
in 82% of countries (Figure 5); however, established choice-
restricted conservative care and conservative care that was cho-
sen or medically advised were available in only 18% of countries,
whereas easy access to conservative care across settings was
available in 27% of countries. Other aspects of conservative care
management, including systematic provision by care providers of
additional training in conservative care and systematic provision
of psychological, cultural, and spiritual support to patients, were
only available in 9% of countries (Figure 3).
Health information systems, statistics, and national health
policies in the Middle East. Health information services for
kidney care, including registries and advocacy groups for
kidney care, were mostly unavailable in many countries in the
Middle East region (Figure 5). A CKD registry was only
available in Oman, which also had the only acute kidney
injury registry in the region. No registries were available in
Syria, United Arab Emirates, and West Bank and Gaza. Eight
countries had a kidney transplant registry. All the registries
mainly had a national coverage (100%), and most wereKidney International Supplements (2021) 11, e47–e56predominantly mandatory (acute kidney injury, 100%; dial-
ysis, 83%; transplant, 88%) (Supplementary Figure S3). There
was variable quality of reporting in the registries, with most
reporting information on patient hospitalization. There were
no countries with acute kidney injury advocacy groups in the
region, 3 countries (Lebanon, Oman, and Saudi Arabia) had
CKD advocacy groups, and 8 countries had a KF/KRT
advocacy group (Figure 5).
A national noncommunicable disease (NCD) strategy was
available in 27%, under development in 9%, and unavailable
in 55% of countries in the region. A national strategy for
improving the care of CKD patients was available in 18% of
countries but was unavailable in 73% (Supplementary
Figure S4). All nondialysis CKD patients (100%) were
covered in the national CKD-specific strategy, whereas 50% of
long-term dialysis and kidney transplant patients were
covered in this strategy (Supplementary Figure S5).
Discussion
The present study reveals major features of KF management
in the ISN Middle East region. By documenting the current
status of kidney care and revealing variation across the re-
gion, our data can be used to improve kidney care in the
region and can lay the foundation for a universal surveillance
network for CKD care in the region. This study showed that
there were significant variations in funding structures,
availability, accessibility, and quality of KF care across
countries in the Middle East region. Our study also
demonstrated a lack of adequate health information about
various aspects of kidney disease and lack of nationale51
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Publicly funded by government; free at the point of delivery Publicly funded by government but with some fees at the point of delivery
Mix of public and private funding systems Solely private and out-of-pocket
Solely private through health insurance Multiple systems: programs provided by government, NGOs, and communities
Other N/A
Figure 2 | Funding structures for nondialysis chronic kidney disease (CKD) and kidney replacement therapy (KRT) care. Values
represent absolute number of countries in each category, expressed as a percentage of total number of countries. HD, hemodialysis; NGOs,
nongovernmental organizations; N/A, not provided; PD, peritoneal dialysis.
I SN pub l i c a f f a i r s A Amouzegar et al.: ISN-GKHA: Middle Eaststrategies for NCDs and strategies for improving the care of
CKD patients across the region.
Middle East countries that are members of the Gulf
Cooperation Council (i.e., Bahrain, Kuwait, Qatar, Oman,
Saudi Arabia, and the United Arab Emirates) have higher na-
tional incomes and, therefore, larger budgets for health ser-
vices, including KRT. Almost two-thirds (63%) of countries in
the Middle East region provide public funding for nondialysis
CKD care, with either no or some OOP fees at the point of care
delivery. In the other one-quarter (27%) of countries, public
and private systems collectively provide funding for nondialysis
CKD. Moreover, no country in the Middle East relies solely on
private and OOP funding for KRT programs, which may
explain both the high accessibility of HD and transplantation
services in the region and the comparable prevalence values of
treated KF in the Middle East and globally (Table 2).10 Studies
have shown that the incidence and prevalence of treated KF,
both indexes of KRT service delivery, ranged from 0 to 175
pmp (mean, <100 pmp) and from 0 to 753 pmp (mean, <250
pmp), respectively, in the Middle East region.26,29–32 In addi-
tion to wide governmental support for KRT, it is equally
important that KRT services should be reasonably priced in the
region to enable countries with low health care budgets to
access KRT. The cost of KRT in the region, although compa-
rable to global values, was excessively high in some countries
(Table 1).10,17
Workforce shortages, especially of nephrologists, constitute
a major constraint to the delivery of kidney care in many partse52of the world. Health care workforce provide leadership and
guide governments on policy making on issues of public
health concerns, as the ongoing coronavirus disease 2019
pandemic has demonstrated across the world. Thus, an
adequate health care workforce remains the pillar of any
country’s health care system, without which universal health
care and sustainable development goals cannot be
attained.33,34 Although this study showed that the median
number of nephrologists in the region was slightly below
global median, there were still some countries in the region
with few nephrologists and trainees. As nephrologists were
primarily responsible for care of KF patients in the region,
efforts should be made to increase training and attract more
trained nephrologists to the region. Also, as some low-income
countries in the region rely on primary care physicians to
provide kidney care, efforts should also go into training and
improving kidney care education for primary care physicians
in the region. Given the shortages of other specialties, espe-
cially access surgeons for KF care in the region, time and
resources need to be also allocated to training these specialists
while simultaneously delegating less specialized tasks to pri-
mary care providers. Notably, no countries in the region re-
ported a shortage of kidney pathologists, specialists who
ensure proper diagnosis and management of primary kidney
diseases.
Long-term HD services were available in all countries, and
HD was the most prevalent type of KRT in the Middle East.
Our findings showed that long-term PD, although available inKidney International Supplements (2021) 11, e47–e56
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Figure 3 | Availability of choice in kidney replacement therapy or conservative kidney management for patients with kidney failure.
Values represent absolute number of countries in each category, expressed as a percentage of total number of countries. HD, hemodialysis; Kt/
V, measure of dialysis adequacy; N/A, not provided; PD, peritoneal dialysis; URR, urea reduction ratio.
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Figure 4 | Accessibility of kidney replacement therapy for patients w
countries in each category, expressed as a percentage of total number
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Figure 5 | Country-level scorecard for kidney care in the International Society of Nephrology Middle East countries. AKI, acute kidney
injury; CKD, chronic kidney disease; CKM, conservative kidney management; HD, hemodialysis; KF, kidney failure; KRT, kidney replacement
therapy; PD, peritoneal dialysis.
I SN pub l i c a f f a i r s A Amouzegar et al.: ISN-GKHA: Middle Eastless common, the advent of automated PD could make it a
more attractive choice for patients.10,27
The availability of kidney transplantation services varied
across the region. Gross national income, municipal education,
governmental conflicts, and funding structures were some
principal factors influencing kidney transplantation pro-
grams.36 Kidney transplantation services were available in most
countries in the Middle East, and organs typically came from
living donors who were related to patients; nonrelatives who
donated organs typically receive monetary compensation.6
Because of a high rate of trauma, deceased organ donation is
highly feasible in the region; however, this source of organs for
transplantation was underutilized in many countries because of
an ongoing religious debate over the nature of brain death and
inadequate public awareness about the importance of organ
donation and transplantation. Religious and social/cultural
acceptance, legal approval for organ donation and trans-
plantation following brain death, and government support are
criteria that must be fully met to establish organ trans-
plantation from deceased donors in the Middle East region.6
Half of the countries in the Middle East region, including
Iran, Jordan, Oman, Kuwait, Qatar, and Saudi Arabia, had
dialysis registries, and 73% had transplant registries. Only one
country (Oman) had a CKD registry. Patients undergoinge54dialysis or transplantation in the region are typically docu-
mented in health systems records and are therefore easier to
track than patients with CKDwho do not need dialysis or other
care that requires tracking for resource allocation purposes.
Despite this, there is evidence that health information systems
for KF and transplantation are incomplete and lacking detail in
most countries in the region.7 Countries with low Human
Development Index scores tend to have high disease burden,
shortages of expert human resources, and underdeveloped
health systems. Countries with Human Development Index
scores at the middle and high end of the spectrum, on the other
hand, have some health-related registry data, assess essential
needs, and try to develop and improve the quality of care and
reduce risk factors of disease, depending on their ability to
access funds.7 However, we believe it is critically important to
also establish databases of CKD patients in the region to enable
better understanding of key patient characteristics, disease
patterns, and resource needs to improve care of patients with
kidney disease in the region. Studies from registry data from the
region have shown comparable results of HD and transplant
patients with data from other parts of the world.37–40
This study also showed that only 27% of countries in the
region had a national NCD strategy, with 9% of countries
reporting an NCD strategy under development. TheseKidney International Supplements (2021) 11, e47–e56
A Amouzegar et al.: ISN-GKHA: Middle East I SN pub l i c a f f a i r sstrategies are important in all countries, and especially in
developing countries to enable early detection and prevention
of NCDs, such as diabetes and hypertension, which are major
causes of kidney disease in the region. Effective prevention
requires coordinated national strategies for tackling NCDs
and CKD risk factors, especially as the burdens of some NCDs
have been projected to rise significantly in the Middle East
over the next decade.41,42 Approaches to improve and increase
early disease detection and preventive measures for CKD and
KF would benefit both patients and the health care systems in
the region by reducing treatment-related costs of kidney
disease. Such strategies should be universal, should be similar
to funding structures for KRT, and should include provision
of funding to improve awareness and ensure early and
adequate treatment of CKD risk factors.
The Middle East is a region with high burden of kidney
disease. This matter of concern must be urgently addressed.
CKD can be prevented in a cost-effective manner when
proper guidelines are followed at the level of primary care. It
is critically important to ensure the appropriate allocation of
funds and health care staff and the affordability of kidney care
and KRT. In addition, well-designed and sustainable registry
systems must be established to help to collect updated data,
develop existing facilities, and address current gaps in kidney
care in the region.
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